Amphastar (AMPH) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the Company’s Abbreviated New Drug Application for teriparatide injection, USP 560 mcg/2.24mL single-patient-use prefilled pen. The FDA determined that Amphastar’s teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar initiated with an Equal Weight at Barclays
- Amphastar Pharmaceuticals’ Resilient Q3 2025 Earnings Call
- Amphastar Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Justify Buy Rating
- Amphastar Pharmaceuticals Reports Q3 2025 Earnings
- Amphastar reports Q3 adjusted EPS 93c, consensus 83c